The role of drugs in countering adverse pathophysiological profiles: Influence on hemodynamics

American Heart Journal

Volumn 114, Issue 4, 1987, Pages 958-964

  Lund Johansen, Per ^a  

^a UNIVERSITY OF BERGEN   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0023637325     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/0002-8703(87)90593-x     Document Type: Article

References (54)

1. Guidelines for the treatment of mild hypertension memorandum from a WHO/ISH meeting
2. MRC trial of treatment of mild hypertension principal results
3. The Australian therapeutic trial in mild hypertension
4. Treatment of mild hypertension: a five-year controlled drug trial. The oslo study
5. State of the art review Hemodynamics in essential hypertension
6. The hemodynamics of essential hypertension
7. Hemodynamic aspects of essential hypertension in humans
8. Physiologic aspects of primary hypertension
9. Doppler evaluation of left ventricular diastolic filling in children with systemic hypertension
10. Hemodynamic effects of antihypertensive agents
11. Exercise and antihypertensive therapy
12. Hemodynamic and hypotensive effects of long-term therapy with chlorothiazide
13. Hemodynamic changes in long-term diuretic therapy of essential hypertension
14. Long-term versus short-term effects of hydrochlorothiazide on renal haemodynamics in essential hypertension
15. Central haemodynamic effects of betablockers in hypertension. A comparison between atenolol, metoprolol, timolol, penbutolol, alprenolol, pindolol and bunitrolol
16. How intrinsic sympathomimetic activity modulates the hemodynamic responses to beta-adrenoceptor antagonists A clue to the nature of antihypertensive mechanism
17. The first dose hemodynamic responses to Visacor (ICI 141–292) in essential hypertension
18. Role of cardiac factors in the initial hypotensive action by beta-adrenoceptor blocking agents
19. Beta-adrenergic blockade in hypertension
20. Short-term hemodynamic adaptation to beta-adrenergic inhibition with atenolol in hypertensive patients
21. Physical performance and muscle metabolism during beta-adrenergic blockade in man
22. Effect of beta-adreneceptor blockade on exercise performance and metabolism
23. 2-Aufnahme und den Kohlenhydratstoffwechsel. Ergometrische Untersuchungen bei Hochdrukkranken
24. Effects of 10 different beta-adrenoceptor antagonists on hemodynamics plasma renin activity and plasma norepinephrine in hypertension the key role of vascular resistance changes in relation to partial agonist activity
25. Effect of acebutolol on left ventricular hemodynamics and anatomy in systemic hypertension
26. Effects of chronic antihypertensive treatment with acebutolol and pindolol on blood pressures, plasma catecholamines, and oxygen uptake at rest and during submaximal and maximal exercise
27. Hemodynamic effects of acebutolol and propranolol in hypertensive patients during exercise
28. Cardiac and renal haemodynamic effects of nadolol
29. Acute and chronic haemodynamic effects of doxazosin in hypertension at rest and during exercise
30. Hemodynamic changes at rest and during exercise in long-term prazosin therapy for essential hypertension
31. Rest and exercise hemodynamic effects of sequential alpha-1-adrenoceptor (trimazosin) and beta-adrenoceptor (propranolol) antagonism in essential hypertension
32. The antihypertensive effects of doxazosin a clinical overview
33. Response of the systemic and pulmonary circulation to labetalol and during exercise
34. Haemodynamic adaptation at rest and during exercise to long-term antihypertensive treatment with combined alpha- and beta-adrenoceptor blockade by labetalol
35. Short- and long-term (six year) hemodynamic effects of labetalol in essential hypertension
36. Pathophysiological background for the use of calcium antagonists
37. Diltiazem. A review of its pharmacological properties and therapeutic efficacy
38. Hemodynamic effects of calcium entry-blocking agents in normal and hypertensive rats and man
39. Hemodynamic long-term effects of verapamil in essential hypertension at rest and during exercise
40. Haemodynamic effects of nifedipine in essential hypertension at rest and during exercise
41. Acute and chronic hemodynamic effects of nisoldipine in essential hypertension at rest and during exercise
42. Acute and chronic sympathetic reflex activation and antihypertensive response to nifedipine
43. Role of calcium antagonists in the treatment of essential hypertension
44. Exercise hemodynamics and oxygen delivery in human hypertension. Response to verapamil
45. Antihypertensive and arterial anticalcinotic effects of calcium antagonists
46. A review of its pharmacodynamic and pharmakokinetic properties, and therapeutic use in hypertension and congestive heart failure
47. Combined captopril and hydrochlorothiazide therapy in severe hypertension: long-term haemodynamic changes at rest and during exercise
48. Long-term haemodynamic effects of enalapril (alone and in combination with hydrochlorothiazide at rest and during exercise in essential hypertension
49. Enalapril, atenolol, and hydrochlorothiazide in mild to moderate hypertension
50. Clinical and hemodynamic experience with enalapril in congestive heart failure
51. Hemodynamic and cardiac effects of centrally acting antihypertensive drugs
52. Beta-blockers in the prevention of myocardial infarction